Elizabeth Bhatt Sells 25,000 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 25,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $7,665,196. This represents a 12.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Septerna Trading Down 1.4%

SEPN opened at $44.50 on Friday. Septerna, Inc. has a 1-year low of $10.74 and a 1-year high of $51.10. The stock has a market capitalization of $2.08 billion, a PE ratio of -82.41 and a beta of 2.29. The firm has a 50-day moving average price of $35.83 and a two-hundred day moving average price of $29.64.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The company had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. On average, research analysts predict that Septerna, Inc. will post -1.32 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on SEPN. HC Wainwright increased their price objective on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday. Guggenheim boosted their target price on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial upped their price target on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Wells Fargo & Company lifted their price objective on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $49.00 price objective on shares of Septerna in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and an average price target of $51.33.

Septerna News Roundup

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: HC Wainwright significantly improved its Septerna earnings outlook, reducing its projected FY2026 loss to $1.15 per share from $2.17 and its FY2027 loss to $1.41 from $3.21. The firm retained a “Buy” rating and a $60 price target, suggesting analysts expect improved financial performance. HC Wainwright forecasts strong price appreciation for Septerna
• Positive Sentiment: HC Wainwright also raised its quarterly 2026 and 2027 EPS forecasts, with projected losses narrowing across every period. The revisions indicate better-than-expected operating trends or a more favorable development outlook for the clinical-stage biotechnology company. HC Wainwright earnings estimate revisions
• Positive Sentiment: JonesTrading raised its price target from $43 to $62 and assigned a “Buy” rating, while Wells Fargo increased its target from $48 to $50 and maintained an “Overweight” rating. These actions reinforce a favorable Wall Street view following Septerna’s recent earnings beat. JonesTrading raises Septerna price target
• Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: the company reported a $0.29-per-share loss versus the anticipated $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate. Septerna shares rise on better-than-expected earnings
• Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at an average price of $44, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale could weigh on sentiment—particularly after the stock’s strong recent advance. Septerna COO insider share sale

Institutional Investors Weigh In On Septerna

A number of institutional investors have recently made changes to their positions in the stock. TRV GP V LLC acquired a new position in Septerna in the second quarter valued at about $208,160,143,000. TRV GP VI LLC bought a new stake in shares of Septerna in the 2nd quarter valued at about $141,048,460,000. Goldman Sachs Group Inc. raised its position in shares of Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the period. BlackRock Inc. bought a new position in Septerna during the 2nd quarter worth approximately $64,706,000. Finally, Vanguard Group Inc. boosted its stake in Septerna by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after acquiring an additional 104,394 shares during the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.